Philadelphia, 3-6 June 2019

Guido Kurz, CEO of Oncostellae, attends the Bio International Convention that takes place on June 3-6, 2019 in Philadelphia.

The company has successfully completed a Phase 1 clinical trial in healthy volunteers with their GI-restricted IBD asset OST-122 and is currently preparing a proof of concept study in patients with ulcerative colitis.

We are actively seeking partnering opportunities before POC.